Skip to content
PubMed This is a summary of 41 peer-reviewed journal articles Updated
Dermatology

Herpetiform pemphigus: A Patient Guide

At a Glance

Herpetiform pemphigus is a rare autoimmune skin disease marked by intense itching and clusters of small blisters. A skin biopsy with immunofluorescence helps distinguish it from similar rashes, while corticosteroids and steroid-sparing medicines support long-term control.

Herpetiform pemphigus (PH) is a rare and often misunderstood member of the pemphigus family of autoimmune diseases. Unlike the more common forms of the condition, which typically cause painful open sores, PH is defined by an intense itch (which varies but is characteristic) and clusters of small blisters [1]. Because these clusters look similar to a herpes infection, hives, or a different condition called dermatitis herpetiformis, many patients spend months or even years searching for the correct name for their symptoms [2]. Understanding that this is an autoimmune condition—where the body mistakenly attacks the adhesion proteins that hold skin cells together—is the first step toward reclaiming control over your health [3].

The biology of the condition is centered on the loss of these adhesion proteins between your skin cells. Your immune system produces autoantibodies that target specific proteins called desmogleins (and sometimes desmocollins), which are essential for keeping the skin’s structure intact [4]. When these proteins are attacked, the skin cells separate, and fluid rushes into the gaps, creating the hallmark blisters and red, hive-like patches. Because PH can look like so many other common rashes, a specialized diagnosis using immunofluorescence is crucial to distinguish it from its look-alikes and ensure the treatment plan is targeting the right biological mechanism [5].

Living with PH means managing a chronic, relapsing-remitting condition. While the initial goal is to stop the immune system’s attack using systemic corticosteroids (for extensive disease), the long-term focus shifts toward finding a sustainable balance [3]. Doctors often introduce “steroid-sparing” medications to help keep the skin clear while minimizing the side effects of long-term steroid use [4]. Although the road can be long and relapses are common, targeted therapies allow many patients to achieve a state of control where they can manage their symptoms and return to their daily routines [6].

Common questions in this guide

What does herpetiform pemphigus look and feel like?
Herpetiform pemphigus is a rare autoimmune skin disease that typically causes intense itching, clusters of small blisters, and red, hive-like patches. Unlike some more common forms of pemphigus, it may not primarily cause painful open sores.
How is herpetiform pemphigus diagnosed?
Diagnosis usually involves a skin biopsy and a specialized test called immunofluorescence. This testing can show the characteristic immune pattern and help distinguish herpetiform pemphigus from herpes infection, hives, and dermatitis herpetiformis.
Which proteins are attacked in herpetiform pemphigus?
The immune system produces antibodies that target desmogleins, proteins that help hold skin cells together. In some people, the antibodies also target related proteins called desmocollins.
What treatments are used for herpetiform pemphigus?
For extensive disease, systemic corticosteroids may be used to suppress the immune attack. Doctors may add steroid-sparing medicines or other targeted treatments to help maintain control while reducing the risks of long-term steroid use.
How can I recognize a relapse of herpetiform pemphigus?
A relapse may begin with returning or worsening intense itching, new clusters of small blisters, or red, hive-like patches. Contact your treating clinician promptly if these symptoms reappear, because early assessment can help guide treatment before the disease becomes widespread.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given how often this is misdiagnosed, what specific markers in my biopsy confirmed I have the herpetiformis variant?
  2. 2.Which 'glue' proteins is my immune system attacking—desmogleins, desmocollins, or both?
  3. 3.How do we determine the right balance between using steroids to stop the itch and adding other medications to protect my long-term health?
  4. 4.What signs of a relapse should I be looking for so we can catch it before it becomes widespread?
  5. 5.How will my treatment plan differ from the standard approach used for more common types of pemphigus?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (6)
  1. 1

    Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria.

    Costa LMC, Cappel MA, Keeling JH

    International journal of dermatology 2019; (58(9)):997-1007 doi:10.1111/ijd.14395.

    PMID: 30900757
  2. 2

    A study of clinical, histopathological and direct immunofluorescence diagnosis in pemphigus group Utility of direct immunofluorescence.

    Hrabovska Z, Jautova J, Hrabovsky V

    Bratislavske lekarske listy 2017; (118(4)):243-249 doi:10.4149/BLL_2017_048.

    PMID: 28471236
  3. 3

    Pemphigus herpetiformis in South Tunisia: a clinical expression of pemphigus foliaceus?

    Jerbi A, Hachicha H, Feki S, et al.

    International journal of dermatology 2018; (57(9)):1094-1101 doi:10.1111/ijd.14139.

    PMID: 30011065
  4. 4

    Pemphigus herpetiformis: a case series and review of the literature.

    Laws PM, Heelan K, Al-Mohammedi F, et al.

    International journal of dermatology 2015; (54(9)):1014-22 doi:10.1111/ijd.12582.

    PMID: 25600350
  5. 5

    Anti-desmocollin autoantibodies in nonclassical pemphigus.

    Ishii N, Teye K, Fukuda S, et al.

    The British journal of dermatology 2015; (173(1)):59-68 doi:10.1111/bjd.13711.

    PMID: 25640111
  6. 6

    Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.

    Boulard C, Duvert Lehembre S, Picard-Dahan C, et al.

    The British journal of dermatology 2016; (175(1)):142-9 doi:10.1111/bjd.14405.

    PMID: 26800395

This page is for informational purposes only and does not constitute medical advice. Your dermatologist or treating clinician should interpret your biopsy and help choose treatment for your situation.

Get notified when new evidence is published on Herpetiform pemphigus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.